SPOTLIGHT -
EP. 1: Updates in Multiple Myeloma in the Frontline Setting
EP. 2: Updates in Relapsed/Refractory Myeloma
EP. 3: Third and Subsequent Line Options for Multiple Myeloma
Epcoritamab Plus Rituximab/Lenalidomide Produces Responses in High-risk R/R Follicular Lymphoma
TTFields Plus SOC Improves OS in Metastatic NSCLC After Progression on Platinum-based Chemotherapy
Liso-Cel Leads to Rapid Responses, High Undetectable MRD Rates in Relapsed/Refractory CLL/SLL
Datopotamab Deruxtecan Plus Pembrolizumab With or Without Chemo Produces Responses in Advanced NSCLC
